At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Hydroxychloroquinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer
In Brief
A Phase 2 clinical trial evaluating Hydroxychloroquine for Pancreatic Cancer. Completed, enrolled 20 participants across 2 sites.
Detailed Summary
Hydroxychloroquine is approved for the treatment of non-cancerous illnesses such as rheumatoid arthritis and systemic lupus erythematous. Researchers in the laboratory have tested tumors from patients with pancreatic cancer and have discovered that they have certain pathways inside the cells that promote growth and survival of the tumor. Hydroxychloroquine may inactivate these pathways and results in the death of pancreatic cancer cells.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesUnited States
CollaboratorsBrigham and Women's Hospital, Massachusetts General Hospital
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2011
First PostedJan 2011
Primary CompletionJan 2013
Study CompletionFeb 2014
TodayJul 2026
First PostedJan 11, 2011
Enrollment StartJan 1, 2011
Primary CompletionJan 1, 2013
Study CompletionFeb 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 15.5 years ago
Interventions
Hydroxychloroquinedrug